M
Michelle Eagle
Researcher at Newcastle University
Publications - 55
Citations - 4091
Michelle Eagle is an academic researcher from Newcastle University. The author has contributed to research in topics: Muscular dystrophy & Duchenne muscular dystrophy. The author has an hindex of 26, co-authored 49 publications receiving 3390 citations. Previous affiliations of Michelle Eagle include Nationwide Children's Hospital.
Papers
More filters
Journal ArticleDOI
A Phase I/II trial of MYO-029 in Adult Subjects with Muscular Dystrophy
Kathryn R. Wagner,James L. Fleckenstein,Anthony A. Amato,Richard J. Barohn,Katharine Bushby,Diana M. Escolar,Kevin M. Flanigan,Alan Pestronk,Rabi Tawil,Gil I. Wolfe,Michelle Eagle,Julaine Florence,Wendy King,Shree Pandya,Volker Straub,Paul Juneau,Kathleen Meyers,Cristina Csimma,Tracey Araujo,Robert Allen,Stephanie A. Parsons,John M. Wozney,Edward R. LaVallie,Jerry R. Mendell +23 more
TL;DR: A safety trial of a neutralizing antibody to myostatin, MYO‐029, in adult muscular dystrophies (Becker muscular dystrophy, facioscapulohumeral dystrophia, and limb‐girdle muscular dy Strophy) is conducted.
Journal ArticleDOI
Prevalence of genetic muscle disease in Northern England: in-depth analysis of a muscle clinic population
Fiona L. M. Norwood,Chris Harling,Patrick F. Chinnery,Michelle Eagle,Kate Bushby,Volker Straub +5 more
TL;DR: A detailed population study of patients with genetic muscle disease in the northern region of England, comparing the case profile with that from Walton and Nattrass' seminal study from 1954, together with data from other more recent studies from around the world.
Journal ArticleDOI
Ataluren treatment of patients with nonsense mutation dystrophinopathy
Katharine Bushby,Richard S. Finkel,Brenda Wong,Richard J. Barohn,Craig Campbell,Giacomo P. Comi,Anne M. Connolly,John W. Day,Kevin M. Flanigan,Nathalie Goemans,Kristi J. Jones,Eugenio Mercuri,Ros Quinlivan,James B. Renfroe,Barry S. Russman,Monique M. Ryan,Mar Tulinius,Thomas Voit,Steven A. Moore,H. Lee Sweeney,Richard T. Abresch,Kim L. Coleman,Michelle Eagle,Julaine Florence,Eduard Gappmaier,Allan M. Glanzman,Erik K Henricson,Jay A. Barth,Gary Elfring,A. Reha,R. Spiegel,Michael W. O'donnell,Stuart W. Peltz,Craig M. McDonald +33 more
TL;DR: As the first investigational new drug targeting the underlying cause of nm‐dystrophinopathy, ataluren offers promise as a treatment for this orphan genetic disorder with high unmet medical need.
Journal ArticleDOI
Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Craig M. McDonald,Craig Campbell,Ricardo Erazo Torricelli,Richard S. Finkel,Richard S. Finkel,Kevin M. Flanigan,Nathalie Goemans,Peter Heydemann,Anna Kamińska,Janbernd Kirschner,Francesco Muntoni,Andrés Nascimento Osorio,Ulrike Schara,Thomas Sejersen,Perry B. Shieh,H. Lee Sweeney,Haluk Topaloglu,Mar Tulinius,Juan J. Vílchez,Thomas Voit,Thomas Voit,Brenda Wong,Gary Elfring,H. Kroger,Xiaohui Luo,Joseph McIntosh,Tuyen Ong,Peter Riebling,Marcio Souza,R. Spiegel,Stuart W. Peltz,Eugenio Mercuri,Lindsay N. Alfano,Michelle Eagle,M. James,Linda Lowes,Anna Mayhew,Elena S. Mazzone,Leslie Nelson,Kristy Rose,Hoda Abdel-Hamid,Susan D. Apkon,Richard J. Barohn,Enrico Bertini,Clemens Bloetzer,Lausanne Canton de Vaud,Russell J. Butterfield,Brigitte Chabrol,Jong-Hee Chae,Daehak-ro Jongno-gu,Giacomi Pietro Comi,Basil T. Darras,Jahannaz Dastgir,Isabelle Desguerre,Raul G Escobar,Erika Finanger,Michela Guglieri,Imelda Hughes,Susan T. Iannaccone,Kristi J. Jones,Peter I. Karachunski,Martin Kudr,Timothy Lotze,Jean K. Mah,Katherine D. Mathews,Yoram Nevo,Julie A. Parsons,Yann Péréon,Alexandra Prufer de Queiroz Campos Araujo,J. Ben Renfroe,Maria Bernadete Dutra de Resende,Monique M. Ryan,Kathryn Selby,Gihan Tennekoon,Giuseppe Vita +74 more
TL;DR: Ataluren was generally well tolerated and most treatment-emergent adverse events were mild to moderate in severity, and there was a significant effect of ataluren in the prespecified subgroup of patients in the intention-to-treat population.
Journal ArticleDOI
THE 6‐minute walk test and other endpoints in Duchenne muscular dystrophy: Longitudinal natural history observations over 48 weeks from a multicenter study
Craig M. McDonald,Erik K Henricson,R. Ted Abresch,Julaine Florence,Michelle Eagle,Eduard Gappmaier,Allan M. Glanzman,R. Spiegel,Jay A. Barth,Gary Elfring,A. Reha,Stuart W. Peltz +11 more
TL;DR: Findings confirm the clinical meaningfulness of the 6MWD as the most accepted primary clinical endpoint in ambulatory DMD trials.